Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2007-10-09
2007-10-09
Yaen, Christopher H. (Department: 1643)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S093700, C424S277100
Reexamination Certificate
active
09866569
ABSTRACT:
Treatment and/or prophylaxis of endothelial dysfunction-related disorders in mammalian patients is effected by administering to the patient effective amounts of apoptotic bodies and/or apoptotic cells.
REFERENCES:
patent: 93/15778 (1993-08-01), None
patent: 96/34613 (1996-11-01), None
patent: WO99/58645 (1999-11-01), None
patent: 00/29003 (2000-05-01), None
patent: WO 00/62788 (2000-10-01), None
Henry F et al Pathobiology 1999; 67(5-6):306-10.
Dini et al (J Cell Sci. 1995; 108:967-973).
Yamaoka et al Jpn Circ J. 1999; 63(12):951-956.
Aukrust et al Ann. Med. 2005;37:74-85.
Bombeli, T., et al., “Apoptotic Vascular Endothelial Cells Become Procoagulant,”Blood, 89:2429-2442 (1997).
Buttke and Sandstrom, et al., “Oxidative Stress As a Mediator of Apoptosis,”Immunology Today, 15:7-10 (1994).
De Caterina, R., “Endothelial dysfunctions: common denominators in vascular disease,”Current Opinions in Lipidology, 11:9-23, (2000).
Fadok, V.A., et al., “Exposure of Phosphatidylserine on the Surface of Apoptotic Lymphocytes Triggers Specific Recognition and Removal by Macrophages,”Journal of Immunology, 148:2207-2216 (1992).
Fadok, V. A., et al., “A receptor for Phosphatidylserine-specific clearance of apoptotic cells,”Nature, 405:85-90 (2000).
Gavrieli, Y., et al., “Identification of Programmed Cell Death In Situ via Specific Labelling of Nuclear DNA Fragmentation,”J. of Cell Biology, 119:493-501 (1992).
Guijarro, C., et al., “3-Hydrxy-3 Methylglutaryl Coenzyme A Reductase and Isoprenylation Inhibitors Induce Apoptosis of Vascular Smooth Muscle in Culture,”Circulation Research, 83:490-500 (1998).
Kerr, et al., “Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics,”British Journal of Cancer, 26:239-257 (1991).
Kondo, et al., “Lymphocyte Function-Associated Antigen-1 is Required for Maximum Elicitation of Allergic Contact Dermatitis,”Br. J. Dermatol.131:354-359 (1994).
Kondo, et al., “Interleukin-10 Inhibits the Elicitation Phase of Allergic Contact Hypersensitity,”The Journal of Investigative Dermatology, 103:811-814 (1994).
Libby, P., “Changing concepts of atherogenesis,”Journal of Internal Medicine, 247:349-358, (2000).
Loo, D. T. and Rillema, J.R., “Measurement of Cell Death,”Methods in Cell Biology, 57:251-264 (1998).
Salvioli, S., et al., “JC-1, but not DiOC6(3) or Rhodamine 123, is a Reliable Fluorescent Probe to Assess Δψ Changes in Intact Dells: Implications For Studies on Mitochondrial Functionality During Apoptosis,”FEBS Letters, 411:77-82 (1997).
Susin, S.A., “Mitochondrial Release of Caspase-2 and -9 During the Apoptotic Process,”Journal of Experimental Medicine, 189:381-394 (1994).
Suzuki, Y., “Cell Death Phagocytosis, and Neurogenesis in Mouse Olfactory Epithelium and Vomeronasal Organ After Colcicine Treatment,”Annals of the New York Academy of Sciences, 855:252-254 (1998).
Teiger, E., “Apoptosis in Pressure Overload-Induced Heart Hypertrophy in the Rat,”Journal of Clinical Investigation, 97:2891-2897 (1996).
Bodey, B., et al. “Apoptosis in the Mammalian Thymus During Normal Histogenesis and Under Various In Vitro and In Vivo Experimental Conditions,”In Vivo, 12(1): 123-134 (1998).
Cooke, E.D., et al. “Treatment of Severe Raynaud's Syndrome by Injection of Autologous Blood Pretreated by Heating, Ozonation and Exposure to Ultraviolet Light (H-O-U) Therapy,”International Angiology, Torino, It. 16(4): 250-254 (1997).
Ganelina, I.E., et al. “Therapy of Severe Steno Cardias by UV Irradiation of the Blood and Some Action Mechanisms of this Therapy,”Folia Haematologica, Akademische Verlagsgesellschaft, Leipzig, DE, 109(3):470-482 (1982).
Shivji, G.M., et al. “Effects of VAS972 Therapy on Allergic Contact Hypersensitivity,”Journal of Investigative Dermatology, New York, NY, 114(4): 862 (2000). (Abstract 675).
M. Marini et al., “Apoptosis of Human Lymphocytes in the Absence or Presence of Internucleosomal DNA Cleavage”Biochemical and Biophysical Research Communications, vol. 229, No. 3, 1996, pp. 910-915.
Shivji, G.M., “Effects of VAS972 Therapy on Allergic Contact Hypersensitivity,”J of Investigative Dermatology114(4):862 (2000).
Bolton Anthony E.
Mandel Arkady
Sauder Daniel N.
Vasogen Ireland Limited
Yaen Christopher H.
LandOfFree
Apoptotic entities for use in treatment of endothelium... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Apoptotic entities for use in treatment of endothelium..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apoptotic entities for use in treatment of endothelium... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3894725